Evidence map›Paper›PMID 38449794›Full record

ArticleOncology letters2024

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Xi Guo, Wenhui Lou, Yaolin Xu, Rongyuan Zhuang, Lie Yao, Junwei Wu, Deliang Fu, Jun Zhang, Jing Liu, Yefei Rong and 14 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Xi GuoDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Wenhui LouDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Yaolin XuDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Rongyuan ZhuangDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Lie YaoDepartment of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Junwei WuOncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
Deliang FuDepartment of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Jun ZhangOncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
Jing LiuOncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
Yefei RongDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Dayong JinDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Wenchuan WuDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Xuefeng XuDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Yuan JiDepartment of Pathology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Lili WuDepartment of Radiotherapy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Minzhi LvDepartment of Biostatistics, Clinical Research Unit, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Xiuzhong YaoDepartment of Radiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Xiaowei LiuDepartment of Anti-tumor Business, Shi Yao Group European Pharmaceutical Co., Ltd., Shijiazhuang, Hebei 050035, P.R. China.
Dansong WangDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Tiantao KuangDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Liang LiuDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Wenquan WangDepartment of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Yuhong ZhouDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Sun Yat-sen University · CNFudan University · CNRuijin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with advanced pancreatic cancer (PC) need a cost-effective treatment regimen. The present study was designed to compare the efficacy and safety of nab-paclitaxel plus S-1 (AS) and gemcitabine plus S-1 (GS) regimens in patients with chemotherapy-naïve advanced PC. In this open-label, multicenter, randomized study named AvGmPC, eligible patients with chemotherapy-naïve advanced PC were randomly assigned (1:1) to receive AS (125 mg/m

Indexed as

first-line chemotherapygemcitabinenab-paclitaxelpancreatic cancerS-1

Identifiers

PMID38449794
PMCPMC10915801
OpenAlexW4391932656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.